Clavis Pharma announces the appointment of Athos Gianella-Borradori, MD
(Thomson Reuters ONE) -
Oslo, Norway, June 24, 2010
Clavis Pharma ASA (OSE: CLAVIS) announces the appointment of Athos
Gianella-Borradori MD as Chief Medical Officer (CMO). Dr Gianella-Borradori is
an experienced onco-hematologist and drug developer, with 30 years experience in
the field. He spent the past 20 years in industry, focused on translational
research and on the clinical development of novel anti-cancer agents. During
this career, he has held managerial and senior clinical research and development
roles at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic
(Germany), Cyclacel (United Kingdom) and, for the last five years, at Serono,
later at Merck Serono (Switzerland).
Before joining the industry, Dr Gianella-Borradori received his medical degree
from the University of Bern (Switzerland). He is board certified in Pediatric
Hematology and Oncology and practised for several years at European and US
universities.
Dr Gianella-Borradori's primary role at Clavis will be to drive the clinical
development of, elacytarabine, which is in a Phase III trial for patients with
acute myeloid leukaemia (AML), and of CP-4126 in partnership with Clovis
Oncology, which is in Phase II for patients with pancreatic cancer. He will also
contribute to shape the strategy of Clavis and will play a major role in the
future developments of Clavis' novel cancer drug candidates.
Olav Hellebø, CEO, said: "We are very pleased that Athos will be joining the
Clavis team as CMO. We believe his extensive international experience in cancer
drug development and clinical experience in oncology and haematology will prove
extremely valuable as we progress our existing clinical programmes and expand
our exciting pipeline of novel LVT-derived cancer candidates. We believe the
improved clinical characteristics of these new drug candidates offer the
potential to make a significant difference to the treatment of patients with a
range a cancer types."
For further information contact:
Olav Hellebø
Chief Executive Officer
+47 24 11 09 50
olav.hellebo(at)clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum(at)clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma(at)citigatedr.co.uk
About Clavis Pharma
Clavis Pharma ASA is a clinical stage oncology drug development company based in
Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These
patented New Chemical Entities (NCEs) are novel, improved versions of
commercially successful drugs, made using Clavis Pharma's Lipid Vector
Technology (LVT) chemistry. Data generated suggests these potential breakthrough
products may offer improved efficacy and reduced side effects through enhanced
pharmacokinetic properties, greater tissue penetration, altered metabolism and,
in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in formal development studies:
* Elacytarabine, an improved form of Ara-C, a leukaemia drug - about to
commence a Phase III randomized, controlled registration study in late-stage
acute myeloid leukaemia;
* Intravenous CP-4126, an improved version of gemcitabine - currently in a
Phase II comparative study with gemcitabine for the treatment of pancreatic
cancer;
* CP-4200, an azacitidine derivative - in preclinical development for
myelodysplastic syndrome (MDS), often a precursor to myeloma or leukaemia.
Clavis Pharma intends to commercialise its products through strategic alliances
and partnerships with experienced oncology businesses and, where and when
commercially appropriate, by establishing its own sales and marketing
capabilities. CP-4126 is licensed to Clovis Oncology in the Americas and Europe.
Clavis Pharma has retained rights in other territories and an option to
co-promote CP-4126 in Europe.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker:
CLAVIS).
Disclaimer
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Clavis Pharma. There are a number
of factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
No expressed or implied representations or warranties are given concerning
Clavis Pharma or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient hereof by virtue of this
News Announcement or the information contained herein.
Clavis Pharma(TM) is a registered trademark of Clavis Pharma ASA.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1426844]
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Clavis Pharma ASA via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 24.06.2010 - 08:52 Uhr
Sprache: Deutsch
News-ID 22954
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharma announces the appointment of Athos Gianella-Borradori, MD"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
